This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Piper Jaffray Appoints Dr. Charles Duncan To Expand Biotechnology Research Platform

Piper Jaffray (NYSE: PJC) is pleased to announce the addition of Dr. Charles Duncan as managing director and senior research analyst in its biotechnology research platform. He will be based in the firm’s New York office, focused specifically on small- and mid-cap emerging growth biotechnology companies.

Duncan brings more than 17 years of sell-side experience, most recently serving as an analyst at JMP Securities since 2002, and previously at Dresdner Kleinwort Wasserstein, Vector Healthcare Group - Prudential Securities, Tucker Anthony Cleary Gull and Chatfield Dean & Co. Duncan has been recognized by industry sources, including the StarMine Analyst Awards, as being among the best analysts for his fundamental and timely analysis.

"Piper Jaffray is highly committed to further advancing its market leading position in specialty areas of healthcare, including biotechnology. Charles adds experience to an already well-established platform, now with a total of four senior analysts and a significant coverage footprint across specialty pharmaceuticals and biotechnology sectors,” commented Jeff Klinefelter, global head of equities for Piper Jaffray. “The firm will continue to focus efforts on providing growth companies with strategic alternatives for funding, while offering investors opportunities to participate in early-stage growth in exciting areas of drug discovery."

Duncan began his career as a manager of clinical development at Global Drug Development, Inc., a pharmaceutical development consulting firm where he also launched InfusionVision Medical, a venture-backed start-up medical device company. He is a graduate of the University of Wisconsin and holds a doctorate in neuropharmacology from the University of Colorado.

Piper Jaffray has a total of 30 senior research analysts located in Minneapolis, New York, San Francisco and Chicago. The firm provides coverage on 565 companies globally in key sectors: business and financial services; clean technology and renewables; consumer; healthcare; industrials; and technology, media and telecommunications.

About Piper JaffrayPiper Jaffray is a leading investment bank and asset management firm serving clients in the U.S. and internationally. Proven advisory teams combine deep industry, product and sector expertise with ready access to capital. Founded in 1895, the firm is headquartered in Minneapolis and has offices across the United States and in London and Zurich.

Since 1895. Member FINRA, NYSE and SIPC.© 2012 Piper Jaffray & Co.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs